Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on LATAM Technology Reporter.
Press releases published on September 8, 2025
INK Entertainment Strengthens Digital Defenses Through Strategic Engagement with CYPFER
Executive Protection and Platform Security Now Central to INK’s Digital Innovation Strategy MIAMI, FL, UNITED STATES, September 8, 2025 /EINPresswire.com/ -- CYPFER, a global authority in digital executive protection and cybersecurity, announces its …
Abivax Presents First Half 2025 Financial Results
Abivax Presents First Half 2025 Financial Results PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing …
Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
GARDEN CITY, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …
Persephone Biosciences Hits 10,000 Families on Waitlist for First-of-Its-Kind Infant Synbiotic
In just over a month, 10,000 parents and caregivers joined the waitlist for Persephone’s science-driven synbiotic designed to restore critical gut microbes in babies. The milestone underscores the urgent demand for solutions that support healthy immune …
Easy Edge Index: Why Easy Edge Index Is Becoming the Core of AI-Based Trading Platform – Read Australia Easy Edge Index Trading App Report!
New York City, NY, Sept. 08, 2025 (GLOBE NEWSWIRE) -- What Is Easy Edge Index? Introduction to AI-Driven Trading in 2025 Easy Edge Index has positioned itself at the forefront of financial technology, providing a modernized framework for trading that …
New Webcast Series by AI/R Company Subsidiary Everymind Highlights Real-World Use Cases of Generative AI and Automation with Agentforce
SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sharing real stories and insights about the application of AI, GenAI, and automation with Agentforce in clients. This is the goal of the new webcast Transform AI, created by Everymind, a subsidiary of AI/R …
Synaptics to demonstrate how AI-native processing enables MSOs and OTT streamers to deliver new features at IBC 2025
AMSTERDAM, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: SYNA) will be at IBC 2025 from September 12-15 with a full program of demonstrations showcasing how embedding artificial intelligence (AI) and AI-native processing in set-top …
Dayforce Flex Work Expands Frontline Contingent Workforce Platform
MINNEAPOLIS and TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management (HCM) leader that makes work life better, today announced a major expansion of its Dayforce Flex Work solution. The enhanced …
Electrify Expo Comes to Chicago for the First Time September 13-14 at NOW Arena, Just Ahead Of The EV Tax Credit Deadline
Lucid will offer public demos of their much-anticipated Gravity model for the first time in the Midwest Flying car from Pivotal, hosted by SoFly, will be on display Tesla will host full self-driving (FSD) and Model Y Robotaxi demos Two ticket options …
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025 NANTES, France, September 8, 2025, 6p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that, …
OSE Immunotherapeutics fait le point sur les procédures en cours avant l’Assemblée Générale Annuelle des actionnaires du 30 septembre 2025
OSE Immunotherapeutics fait le point sur les procédures en cours avant l’Assemblée Générale Annuelle des actionnaires du 30 septembre 2025 NANTES, France – 8 septembre 2025, 18 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’ …
super{set} Unveils 2025 super{summit} in San Francisco: outside{in} Theme Focuses on AI-Native Company Building
SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- super{set}, based in San Francisco and dedicated to founding, funding and building data and AI-native startups, announced its upcoming super{summit}, to be held September 10-12, 2025, at The Pearl in the …
Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025
Analysis of the FAERS database shows that the real-world abuse potential of the DORA class is very low and markedly less than those seen for other scheduled and non-scheduled insomnia therapies Allschwil, Switzerland – September 8, 2025 Idorsia Ltd (SIX: …
BIO CEO John Crowley to Receive Prestigious Dennis K. Stone Award at BioNTX iC³® Summit
DALLAS, Sept. 08, 2025 (GLOBE NEWSWIRE) -- BioNTX proudly announces that John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), has been named the 2025 recipient of the Dennis K. Stone Award, the highest recognition bestowed by …
Society Pass Inc (Nasdaq: SOPA) Maintains Compliance with Nasdaq Continued Listing Requirements
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Society Pass Incorporated (Nasdaq: SOPA) (“SoPa” or the “Company”), a Southeast Asia-based (SEA) investment holding company, today announces a Form 8-K filing with the Securities and Exchange Commission (“SEC”). …
Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs
Daten zur Kombination des bispezifischen PD-L1xVEGF-A-Antikörper-Kandidaten Pumitamig (BNT327/BMS986545) mit Chemotherapie zeigen weiterhin ermutigende Anti-Tumor-Aktivitäten bei Patientinnen und Patienten mit kleinzelligem Lungenkrebs im fortgeschrittenen …
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), expanding evidence for its potential to set a new standard …
Dev Barometer: AI Saves Developers Nearly a Full Workday Per Week on Coding
MOUNTAIN VIEW, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BairesDev® launches its first quarterly Dev Barometer – the most up-to-date survey of senior software engineers and project managers (PMs) across 100+ industries and 63 countries. The inaugural …